ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 554.3 | 602.1 | 496.4 |
| Other income | 3.5 | 15.5 | 9.9 |
| Total income | 557.8 | 617.7 | 506.3 |
| Profit before exceptional items & tax | 98.0 | 138.9 | 80.7 |
| Exceptional items | 0.0 | 0.3 | 0.0 |
| Profit before tax | 98.0 | 139.2 | 80.7 |
| Net profit | 73.3 | 104.2 | 60.5 |
| Operating margin | 17.6% | 22.5% | 15.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +21.20% |
|---|---|
| Net profit, quarter on quarter | -29.70% |
| Revenue, year on year | +11.70% |
| Operating profit, year on year | +33.50% |
| Operating profit, quarter on quarter | -23.40% |
BSE results filing, NSE: SAILIFE. Figures extracted from the filing.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,910.70
- Market cap
- ₹40,618 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 108.0×Sector 43.8×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Other Announcement
Sai Life Sciences filed a Crisil monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. It is a routine SEBI-mandated compliance certificate with no transaction or business event.
Sai Life Science Earnings Call Transcript: Key Takeaways
Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Sai Life Science Investor Presentation: Key Takeaways
H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.
Sai Life Science Results Update
Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 108,005 ESOP equity shares, taking paid-up capital to Rs.21.26 Crore. No stated consideration means no event value.
Sai Life Science Management Change
Sai Life Sciences appointed three senior management personnel effective 5 November 2026. The appointees include Sidhartha Das as Senior Vice President and Head of Human Resources.